Cost-effectiveness analysis of sintilimab vs. placebo in combination with chemotherapy as first-line therapy for local advanced or metastatic oesophageal squamous cell carcinoma

OBJECTIVE: Results of Orient 15 indicated the health benefits to patients with local advanced or metastatic oesophageal squamous cell carcinoma (OSCC). This study aimed to evaluate the cost-effectiveness of sintilimab plus chemotherapy in treating OSCC from the perspective of Chinese healthcare syst...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Taihang, Zhao, Mingye, Tang, Wenxi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763586/
https://www.ncbi.nlm.nih.gov/pubmed/36561521
http://dx.doi.org/10.3389/fonc.2022.953671

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763586/
https://www.ncbi.nlm.nih.gov/pubmed/36561521
http://dx.doi.org/10.3389/fonc.2022.953671

Ejemplares similares